PSMF1

Summary

PSMF1 (proteasome inhibitor subunit 1, HGNC:9571) is a protein-coding gene on chromosome 20p13, encoding Proteasome inhibitor PI31 subunit (Q92530). Plays an important role in control of proteasome function. It is a selective cancer dependency (DepMap: 16.1% of cell lines).

The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a protein that inhibits the activation of the proteasome by the 11S and 19S regulators. Alternative transcript variants have been identified for this gene.

Source: NCBI Gene 9491 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder with motor features (Strong, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 69 total — 1 pathogenic
• Cancer dependency (DepMap): dependent in 16.1% of screened cell lines
• MANE Select transcript: NM_006814

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9571
Approved symbol	PSMF1
Name	proteasome inhibitor subunit 1
Location	20p13
Locus type	gene with protein product
Status	Approved
Aliases	PI31
Ensembl gene	ENSG00000125818
Ensembl biotype	protein_coding
OMIM	617858
Entrez	9491

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 13 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000246015, ENST00000333082, ENST00000335877, ENST00000381898, ENST00000381899, ENST00000418246, ENST00000435720, ENST00000478004, ENST00000479715, ENST00000484891, ENST00000652336, ENST00000879396, ENST00000879397, ENST00000879398, ENST00000879399, ENST00000937764, ENST00000937765, ENST00000954240

RefSeq mRNA: 6 — MANE Select: NM_006814 NM_001323407, NM_001323408, NM_001323409, NM_001323410, NM_006814, NM_178578

CCDS: CCDS13010, CCDS82589

Canonical transcript exons

ENST00000335877 — 7 exons

Exon	Start	End
ENSE00003471528	1125498	1125650
ENSE00003545681	1127426	1127508
ENSE00003547538	1165029	1172246
ENSE00003628741	1163130	1163183
ENSE00003659963	1164318	1164476
ENSE00003788943	1135121	1135306
ENSE00003841897	1118602	1118902

Expression profiles

Bgee: expression breadth ubiquitous, 302 present calls, max score 99.35.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 86.3669 / max 3292.3946, expressed in 1826 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
183079	78.3257	1826
183085	3.7673	1579
183086	1.4766	1020
183080	1.1178	107
183089	0.9777	616
183084	0.3434	151
183082	0.2455	4
183077	0.0880	3
183078	0.0117	4
183075	0.0112	3

Top tissues by expression

303 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.35	gold quality
male germ cell	CL:0000015	99.02	gold quality
left testis	UBERON:0004533	98.67	gold quality
right testis	UBERON:0004534	98.66	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.63	gold quality
blood	UBERON:0000178	97.55	gold quality
gastrocnemius	UBERON:0001388	97.35	gold quality
testis	UBERON:0000473	97.34	gold quality
popliteal artery	UBERON:0002250	97.28	gold quality
tibial artery	UBERON:0007610	97.28	gold quality
monocyte	CL:0000576	97.18	gold quality
islet of Langerhans	UBERON:0000006	97.11	gold quality
right coronary artery	UBERON:0001625	97.10	gold quality
stromal cell of endometrium	CL:0002255	97.07	gold quality
muscle of leg	UBERON:0001383	96.98	gold quality
ganglionic eminence	UBERON:0004023	96.97	gold quality
leukocyte	CL:0000738	96.96	gold quality
mononuclear cell	CL:0000842	96.95	gold quality
bone marrow cell	CL:0002092	96.90	gold quality
aorta	UBERON:0000947	96.84	gold quality
left coronary artery	UBERON:0001626	96.65	gold quality
mucosa of stomach	UBERON:0001199	96.54	gold quality
cortical plate	UBERON:0005343	96.45	gold quality
peripheral nervous system	UBERON:0000010	96.43	gold quality
nerve	UBERON:0001021	96.43	gold quality
tibial nerve	UBERON:0001323	96.43	gold quality
endocervix	UBERON:0000458	96.37	gold quality
coronary artery	UBERON:0001621	96.37	gold quality
ventricular zone	UBERON:0003053	96.36	gold quality
thoracic aorta	UBERON:0001515	96.34	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	31.63
E-MTAB-9221	yes	11.05
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

216 targeting PSMF1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-6721-5P	99.93	68.92	2981

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 16.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 4)

• a model for FP domain-mediated dimerization of SCF(Fbxo7) and PI31 (PMID:18495667)
• cellular roles and mechanisms of PI31 in regulation of proteasome function remain unclear and require future definition. (PMID:24770418)
• NOD2 and TLR2 Signal via TBK1 and PI31 to Direct Cross-Presentation and CD8 T Cell Responses. (PMID:31114588)
• Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. (PMID:33651148)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	psmf1	ENSDARG00000022652
mus_musculus	Psmf1	ENSMUSG00000032869
rattus_norvegicus	Psmf1	ENSRNOG00000009640
drosophila_melanogaster	CG12729	FBGN0029816
drosophila_melanogaster	PI31	FBGN0033669

Protein

Protein identifiers

Proteasome inhibitor PI31 subunit — Q92530 (reviewed: Q92530)

All UniProt accessions (6): Q92530, A0A140VJT2, F5H4Z3, H0Y555, Q5QPM7, Q5QPM9

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in control of proteasome function. Inhibits the hydrolysis of protein and peptide substrates by the 20S proteasome. Also inhibits the activation of the proteasome by the proteasome regulatory proteins PA700 and PA28.

Subunit / interactions. Monomer and homodimer. Interacts with FBXO7. Interacts with the 20S proteasome.

Subcellular location. Cytoplasm. Endoplasmic reticulum.

Similarity. Belongs to the proteasome inhibitor PI31 family.

RefSeq proteins (6): NP_001310336, NP_001310337, NP_001310338, NP_001310339, NP_006805, NP_848693 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013886	PI31_Prot_C	Domain
IPR021625	PI31_Prot_N	Domain
IPR045128	PI31-like	Family

Pfam: PF08577, PF11566

UniProt features (34 total): helix 7, strand 7, modified residue 6, turn 4, mutagenesis site 3, sequence variant 2, region of interest 2, initiator methionine 1, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
4OUH	X-RAY DIFFRACTION	2
2VT8	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92530-F1	75.15	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 252, 2, 153, 205, 219, 231

Mutagenesis-validated functional residues (3):

Position	Phenotype
6	abolishes homodimerization.
83	abolishes interaction with fbxo7, but has no effect on homodimerization; when associated with e-90.
90	abolishes interaction with fbxo7, but has no effect on homodimerization; when associated with e-83.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9907900	Proteasome assembly

MSigDB gene sets: 213 (showing top): GGGACCA_MIR133A_MIR133B, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, MORF_MSH3, KEGG_PROTEASOME, MORF_BRCA1, MORF_ATRX, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, ATGCAGT_MIR217, MORF_ESR1, CACCAGC_MIR138, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, EFC_Q6

GO Biological Process (3): ubiquitin-dependent protein catabolic process (GO:0006511), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), negative regulation of proteasomal protein catabolic process (GO:1901799)

GO Molecular Function (5): endopeptidase inhibitor activity (GO:0004866), protein homodimerization activity (GO:0042803), protein heterodimerization activity (GO:0046982), proteasome binding (GO:0070628), protein binding (GO:0005515)

GO Cellular Component (7): endoplasmic reticulum (GO:0005783), cytosol (GO:0005829), proteasome core complex (GO:0005839), membrane (GO:0016020), perinuclear region of cytoplasm (GO:0048471), proteasome complex (GO:0000502), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cytoplasm	3
proteasomal protein catabolic process	2
protein dimerization activity	2
intracellular protein-containing complex	2
protein ubiquitination	1
modification-dependent protein catabolic process	1
ubiquitin-dependent protein catabolic process	1
negative regulation of protein catabolic process	1
regulation of proteasomal protein catabolic process	1
endopeptidase activity	1
peptidase inhibitor activity	1
endopeptidase regulator activity	1
identical protein binding	1
protein-containing complex binding	1
binding	1
endomembrane system	1
intracellular membrane-bounded organelle	1
proteasome complex	1
catalytic complex	1
endopeptidase complex	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1242 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PSMF1	PSME4	Q14997	819
PSMF1	PSME3	P61289	763
PSMF1	FBXO7	Q9Y3I1	714
PSMF1	PSMB10	P40306	553
PSMF1	PSMG4	Q5JS54	540
PSMF1	PSMD12	O00232	515
PSMF1	PSMC4	P43686	508
PSMF1	ECPAS	Q5VYK3	506
PSMF1	PSMB7	Q99436	501
PSMF1	PSMD9	O00233	494
PSMF1	PSMC6	P49719	489
PSMF1	CDK6	Q00534	457
PSMF1	PSMD4	P55036	453
PSMF1	POMP	Q9Y244	453
PSMF1	AMN1	Q8IY45	448

IntAct

140 interactions, top by confidence:

A	B	Type	Score
PSMA1	PSMA7	psi-mi:“MI:0914”(association)	0.950
PSMF1	FBXO7	psi-mi:“MI:0915”(physical association)	0.930
FBXO7	PSMF1	psi-mi:“MI:0915”(physical association)	0.930
FBXO7	SKP1	psi-mi:“MI:0914”(association)	0.900
PSMA2	PSMA7	psi-mi:“MI:0914”(association)	0.850
PSMG2	PSMG1	psi-mi:“MI:0914”(association)	0.850
PSMA5	PSMA7	psi-mi:“MI:0914”(association)	0.800
PSMB7	PSMA7	psi-mi:“MI:0914”(association)	0.790
PSMB2	PSMA7	psi-mi:“MI:0914”(association)	0.790
NHERF2	PODXL	psi-mi:“MI:0914”(association)	0.770
PSMB3	PSMA7	psi-mi:“MI:0914”(association)	0.770
PSMB2	PSMD11	psi-mi:“MI:0914”(association)	0.730
PSMB4	PSMA7	psi-mi:“MI:0914”(association)	0.730
PSMA7	PSMF1	psi-mi:“MI:0915”(physical association)	0.660
PSMF1	PSMA7	psi-mi:“MI:0914”(association)	0.660
PSMB3	PSMD11	psi-mi:“MI:0914”(association)	0.640
PSMB7	PSMD11	psi-mi:“MI:0914”(association)	0.640
PSMF1	PSMB1	psi-mi:“MI:0914”(association)	0.640
PSMB1	PSMA7	psi-mi:“MI:0914”(association)	0.640

BioGRID (171): FBXO7 (Two-hybrid), PSMA2 (Reconstituted Complex), PSMA2 (Co-fractionation), PSMF1 (Reconstituted Complex), PSMC1 (Reconstituted Complex), PSMD8 (Reconstituted Complex), PSMC3 (Reconstituted Complex), PSMD4 (Co-fractionation), HIST1H1A (Affinity Capture-MS), PSMA1 (Affinity Capture-MS), PSMF1 (Affinity Capture-MS), PSMF1 (Affinity Capture-MS), PSMF1 (Affinity Capture-MS), PSMF1 (Affinity Capture-MS), PSMF1 (Affinity Capture-MS)

ESM2 similar proteins: B0BN56, F4J077, F7C1E2, O00165, O35387, O35723, O54946, O75190, P12812, P25686, P58340, P70302, P84903, Q04757, Q08A72, Q0IHF9, Q13586, Q15773, Q22472, Q28C44, Q2KIE2, Q2TBE0, Q32KY3, Q3SX30, Q58CP9, Q5F3Z5, Q5R4T3, Q5R8H0, Q5XIU5, Q61733, Q68EU0, Q6AX41, Q6AYU3, Q6GNW0, Q7TSE9, Q80UP5, Q862Z4, Q8BHL8, Q8H1E8, Q8IZ07

Diamond homologs: Q3SX30, Q5RDN3, Q5XIU5, Q8BHL8, Q92530

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
PSMF1	“down-regulates activity”	“26S Proteasome”	binding
TNKS2	“down-regulates quantity by destabilization”	PSMF1	ADP-ribosylation
TNKS	“down-regulates quantity by destabilization”	PSMF1	ADP-ribosylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 87 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Antigen processing: Ub, ATP-independent proteasomal degradation	11	95.2×	2e-19
Proteasome assembly	20	61.8×	2e-29
Vpu mediated degradation of CD4	15	60.4×	2e-22
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis	16	60.2×	2e-23
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2	16	60.2×	2e-23
Regulation of activated PAK-2p34 by proteasome mediated degradation	14	59.1×	6e-21
SCF-beta-TrCP mediated degradation of Emi1	16	57.7×	2e-23
Degradation of DVL	16	57.7×	2e-23

GO biological processes:

GO term	Partners	Fold	FDR
regulation of alternative mRNA splicing, via spliceosome	5	14.9×	4e-03
proteasome-mediated ubiquitin-dependent protein catabolic process	20	12.7×	3e-14

Disease & clinical

Clinical variants and AI predictions

ClinVar

69 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	47
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
4820252	GRCh37/hg19 20p13(chr20:61568-1700861)x1	Pathogenic

SpliceAI

1670 predictions. Top by Δscore:

Variant	Effect	Δscore
20:1118858:G:GT	donor_gain	1.0000
20:1118858:G:T	donor_gain	1.0000
20:1125481:AACT:A	acceptor_gain	1.0000
20:1125482:ACTGT:A	acceptor_gain	1.0000
20:1125484:T:A	acceptor_gain	1.0000
20:1125486:T:TA	acceptor_gain	1.0000
20:1125496:AGCC:A	acceptor_gain	1.0000
20:1125496:AGCCG:A	acceptor_gain	1.0000
20:1125497:GCC:G	acceptor_gain	1.0000
20:1125497:GCCG:G	acceptor_gain	1.0000
20:1125497:GCCGG:G	acceptor_gain	1.0000
20:1125649:TGG:T	donor_loss	1.0000
20:1125651:G:T	donor_loss	1.0000
20:1125652:T:TC	donor_loss	1.0000
20:1125653:G:GT	donor_loss	1.0000
20:1125654:AGTC:A	donor_loss	1.0000
20:1127425:GGAAT:G	acceptor_gain	1.0000
20:1118898:ACCAG:A	donor_gain	0.9900
20:1118899:CCAG:C	donor_loss	0.9900
20:1118900:CAGGT:C	donor_loss	0.9900
20:1118901:AGGTA:A	donor_loss	0.9900
20:1118902:GG:G	donor_loss	0.9900
20:1118904:T:A	donor_loss	0.9900
20:1124469:G:GT	donor_gain	0.9900
20:1125481:A:AG	acceptor_gain	0.9900
20:1125482:A:G	acceptor_gain	0.9900
20:1125482:ACT:A	acceptor_gain	0.9900
20:1125487:G:A	acceptor_gain	0.9900
20:1125493:CCCA:C	acceptor_loss	0.9900
20:1125494:CCA:C	acceptor_loss	0.9900

AlphaMissense

1760 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:1164439:T:C	F243L	0.997
20:1164441:T:A	F243L	0.997
20:1164441:T:G	F243L	0.997
20:1125540:T:A	W58R	0.996
20:1125540:T:C	W58R	0.996
20:1164440:T:C	F243S	0.992
20:1164440:T:G	F243C	0.991
20:1125573:T:G	Y69D	0.986
20:1135144:T:C	L130P	0.986
20:1164436:C:A	R242S	0.986
20:1118855:T:A	W28R	0.985
20:1118855:T:C	W28R	0.985
20:1118843:T:C	C24R	0.984
20:1164422:T:A	V237E	0.983
20:1164434:C:A	A241D	0.983
20:1164443:A:G	D244G	0.983
20:1125601:T:C	L78P	0.982
20:1125542:G:C	W58C	0.980
20:1125542:G:T	W58C	0.980
20:1135125:T:G	Y124D	0.979
20:1135144:T:A	L130H	0.979
20:1125529:T:G	L54R	0.978
20:1125571:G:C	R68P	0.978
20:1127460:T:C	L106P	0.978
20:1164448:T:C	F246L	0.976
20:1164450:T:A	F246L	0.976
20:1164450:T:G	F246L	0.976
20:1164407:T:A	L232H	0.975
20:1125529:T:A	L54Q	0.974
20:1125568:T:C	L67P	0.974

dbSNP variants (sampled 300 via entrez): RS1000035453 (20:1147587 G>A), RS1000037453 (20:1116297 G>A,T), RS1000041244 (20:1111433 T>C), RS1000041602 (20:1113304 T>A,C), RS1000107092 (20:1154090 C>A), RS1000174777 (20:1152421 A>G), RS1000217071 (20:1140999 A>G), RS1000278392 (20:1147948 A>G), RS1000303394 (20:1135011 A>G), RS1000310641 (20:1153697 C>T), RS1000440269 (20:1134770 C>G), RS1000514566 (20:1138130 C>A), RS1000536467 (20:1154900 G>A), RS1000565464 (20:1138548 A>T), RS1000672909 (20:1150352 C>T)

Disease associations

OMIM: gene MIM:617858 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder with motor features	Strong	Autosomal recessive

Mondo (2): complex neurodevelopmental disorder with motor features (MONDO:0100516), disease (MONDO:0000001)

Orphanet (1): (Orphanet:377788)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004029_2	Angiotensin-converting enzyme inhibitor intolerance	6.000000e-06
GCST006994_4	Logical memory (immediate recall) in Alzheimer’s disease dementia	5.000000e-07
GCST011780_1	Neonatal white matter microstructure	5.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005325	response to angiotensin-converting enzyme inhibitor
EFO:0004874	memory performance
EFO:0005674	white matter microstructure measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D004194	Disease	C23.550.288

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression, increases methylation	4
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
Valproic Acid	increases expression, decreases methylation	2
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
nobiletin	decreases reaction, increases expression	1
sodium arsenate	decreases reaction, increases expression	1
beta-lapachone	decreases expression	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
nickel sulfate	decreases expression	1
CGP 52608	affects binding, increases reaction	1
CD 437	decreases expression	1
3-(4’-hydroxy-3’-adamantylbiphenyl-4-yl)acrylic acid	decreases expression	1
bisphenol S	decreases methylation	1
bisphenol AF	increases expression	1
Bortezomib	decreases expression	1
Temozolomide	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Calcitriol	decreases expression	1
Carbamazepine	affects expression	1
Diclofenac	affects expression	1
Doxorubicin	increases expression	1
Ivermectin	decreases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Rotenone	decreases expression	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1LH	Abcam Jurkat PSMF1 KO	Cancer cell line	Male
CVCL_D1Q8	Abcam K-562 PSMF1 KO	Cancer cell line	Female
CVCL_D2LU	Abcam Raji PSMF1 KO	Cancer cell line	Male
CVCL_TH36	HAP1 PSMF1 (-) 1	Cancer cell line	Male
CVCL_TH37	HAP1 PSMF1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00502970	PHASE4	COMPLETED	Short Course of Interferon Treatment in Patients With HCV Infection
NCT00632554	PHASE4	COMPLETED	The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia
NCT01179191	PHASE4	TERMINATED	Conversion to Embeda With Rescue Trial
NCT01968161	PHASE4	UNKNOWN	Investigator Initiated Study - Asenapine Early Psychosis
NCT02436980	PHASE4	COMPLETED	Premedication for ERCP With Midazolam or Tramadol
NCT03702361	PHASE4	COMPLETED	Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease
NCT06271538	PHASE4	RECRUITING	Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
NCT06390436	PHASE4	NOT_YET_RECRUITING	Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
NCT06750471	PHASE4	ACTIVE_NOT_RECRUITING	Dupixent Study for Alternate Administration
NCT00096785	PHASE3	COMPLETED	Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
NCT00569595	PHASE3	COMPLETED	Improving Health Habits in Impoverished Populations
NCT00787956	PHASE3	COMPLETED	Internet Chronic Disease Self-Management Program for Australia
NCT00803244	PHASE3	COMPLETED	Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis
NCT00813189	PHASE3	COMPLETED	Efficacy Study of Recombinant Growth Hormone on Muscle Function in Children Long-term Treated With Glucocorticoid
NCT00911287	PHASE3	COMPLETED	Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain
NCT01237860	PHASE3	COMPLETED	Evaluation of the Safety and Performance of the NESS L300 Plus System
NCT01477281	PHASE3	UNKNOWN	Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon
NCT02137772	PHASE3	COMPLETED	Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
NCT04007848	PHASE3	COMPLETED	Cobimetinib for BRAF-wild-type or Mutated Histiocytoses
NCT04264897	PHASE3	COMPLETED	Antecedent Metabolic Health and Metformin Aging Study
NCT04639310	PHASE3	TERMINATED	XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
NCT04912856	PHASE3	TERMINATED	An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
NCT00003145	PHASE2	COMPLETED	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
NCT00036738	PHASE2	COMPLETED	Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
NCT00408252	PHASE2	TERMINATED	Efficacy of SU 011248 in Head And Neck Carcinoma
NCT00552461	PHASE2	COMPLETED	Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
NCT00795132	PHASE2	COMPLETED	Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
NCT00889499	PHASE2	COMPLETED	Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron
NCT01047514	PHASE2	COMPLETED	Healthier Living Canada
NCT01047774	PHASE2	TERMINATED	The Effect of Soy Protein on Post- Breast Cancer Surgery Pain
NCT01215578	PHASE2	TERMINATED	Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
NCT01267253	PHASE2	COMPLETED	Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01325194	PHASE2	COMPLETED	CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis
NCT01326897	PHASE2	COMPLETED	Healthy Homes/Healthy Families
NCT01635270	PHASE2	COMPLETED	Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma
NCT01664663	PHASE2	TERMINATED	Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy
NCT01687777	PHASE2	UNKNOWN	Mensenchymal Stem Cell (MSC) Included in OrthADAPT Membrane for Rotator Cuff Tears Repair
NCT01737450	PHASE2	COMPLETED	Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
NCT01794845	PHASE2	TERMINATED	Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
NCT01884389	PHASE2	COMPLETED	Randomized Trial of an HIV Navigation Program for Early Palliative Care